FOI2021/00496: COVID Arcadia Trial
Case reference FOI2021/00496
Published 4 January 2022
Request
Request Received: 15 November 2021
I am emailing today in the hopes of enquiring to the status of the Arcadia trial, in relation to drug AZD1656.
There are a number of national and international interested parties in this trial and the progress has now been thrown even more into the spotlight by the recent "Merck pill" development.
The last results came over 2 months ago, on 9th September where the public were told that the results of Phase 2 had been successful and immediate commercial discussions for licensing or fundraising for Phase 3 would begin. This had been expected as the narrative for the last year had been that commercialisation was always on the cusp and awaiting confirmation of Phase 2.
I would like to understand how this vital trial has progressed in the last 2 months and whether there is any information you are able to provide.
Response
Response Sent: 24 November 2021
Full details of this response are provided in the attached document.
Documents
This is UK Research and Innovation's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.